Dr. Michel J. Tremblay is a regular researcher in the field of infectious and immune diseases at the CHU Research Center of Québec-Laval University. He is also a Professor in the Department of Microbiology-Infectiology and Immunology of the School of Medicine at Laval University, and holds the Canada Research Chair in Human Immuno-Retrovirology.

He has been Vice-Dean, Research and Graduate Studies at the Faculty of Medicine, and is currently Assistant Vice-President, Research, Creation and Innovation at Laval University. Dr. Tremblay has published over 200 articles in peer-reviewed scientific journals, and to date has received nearly $ 15 million in funding as a principal investigator and just under $ 40 million in funding as co-researcher for his research projects. Dr. Tremblay has received several awards and distinctions, including the André Dupont Award from the Clinical Research Club of Quebec and the Léo-Pariseau Award from ACFAS. Dr. Tremblay is a member of the Canadian Research Consortium on HIV Healing (CanCURE) which is funded by the Canadian Institutes of Health Research (CIHR).

His research aims to deepen our knowledge of the pathogenesis of human immunodeficiency virus (HIV) infection, the etiologic agent of Acquired Immunodeficiency Syndrome (AIDS). His research focuses on several facets of HIV infection, such as the complex interactions that occur between HIV and certain target cells of the virus (e.g., macrophages, CD4 T cells, astrocytes, etc.) and large-scale analysis of gene expression patterns following viral infection, using DNA microarrays and RNA sequencing in combination with powerful bioinformatic tools.

CHUL
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2
197 entries « 19 of 20 »

Cantin R, Fortin JF, Lamontagne G, Tremblay M

The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity.

Journal Article

J Virol, 71 (3), pp. 1922-30, 1997, ISSN: 0022-538X.

Abstract | Links:

Briand G, Barbeau B, Tremblay M

Binding of HIV-1 to its receptor induces tyrosine phosphorylation of several CD4-associated proteins, including the phosphatidylinositol 3-kinase.

Journal Article

Virology, 228 (2), pp. 171-9, 1997, ISSN: 0042-6822.

Abstract | Links:

Bernier R, Tremblay M, Tsoukas C, Bergeron MG

Drug sensitivity of human immunodeficiency virus type 1 isolates after ribavirin therapy.

Journal Article

J Infect Dis, 175 (1), pp. 176-8, 1997, ISSN: 0022-1899.

Abstract | Links:

Harvie P, Omar RF, Dusserre N, Lansac N, Désormeaux A, Gourde P, Simard M, Tremblay M, Beauchamp D, Bergeron MG

Ribavirin potentiates the efficacy and toxicity of 2',3'- dideoxyinosine in the murine acquired immunodeficiency syndrome model.

Journal Article

J Pharmacol Exp Ther, 279 (2), pp. 1009-17, 1996, ISSN: 0022-3565.

Abstract | Links:

Harvie P, Omar RF, Dusserre N, Désormeaux A, Gourde P, Tremblay M, Beauchamp D, Bergeron MG

Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model.

Journal Article

J Acquir Immune Defic Syndr Hum Retrovirol, 12 (5), pp. 451-61, 1996, ISSN: 1077-9450.

Abstract | Links:

Omar RF, Gourde P, Désormeaux A, Tremblay M, Beauchamp D, Bergeron MG

In vivo toxicity of foscarnet and zidovudine given alone or in combination.

Journal Article

Toxicol Appl Pharmacol, 139 (2), pp. 324-32, 1996, ISSN: 0041-008X.

Abstract | Links:

Tremblay MJ, Olivier M, Bernier R

Leishmania and the pathogenesis of HIV infection.

Journal Article

Parasitol Today, 12 (7), pp. 257-61, 1996, ISSN: 0169-4758.

Abstract | Links:

Cantin R, Fortin JF, Tremblay M

The amount of host HLA-DR proteins acquired by HIV-1 is virus strain- and cell type-specific.

Journal Article

Virology, 218 (2), pp. 372-81, 1996, ISSN: 0042-6822.

Abstract | Links:

Harvie P, Désormeaux A, Bergeron MC, Tremblay M, Beauchamp D, Poulin L, Bergeron MG

Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine.

Journal Article

Antimicrob Agents Chemother, 40 (1), pp. 225-9, 1996, ISSN: 0066-4804.

Abstract | Links:

Corbeil J, Tremblay M, Richman DD

HIV-induced apoptosis requires the CD4 receptor cytoplasmic tail and is accelerated by interaction of CD4 with p56lck.

Journal Article

J Exp Med, 183 (1), pp. 39-48, 1996, ISSN: 0022-1007.

Abstract | Links:

197 entries « 19 of 20 »
Signaler des ajouts ou des modifications

Active projects

  • Canadian HIV Cure Enterprise 2.0: Targeting the interplay between myeloid cells and C04+ T-cells for HIV cure, Subvention, Instituts de recherche en santé du Canada, Subvention d'équipe : Recherche biomédicale et clinique sur le VIH/sida, from 2019-04-01 to 2024-03-31
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche en infectiologie, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2024-11-06
  • Chaire du recherche du Canada en immuno-rétrovirologie humaine, Subvention, Secrétariat des Chaires de recherche du Canada, Chaires de recherche du Canada - Fonctionnement, from 2015-01-01 to 2021-12-31

Recently finished projects

  • Development of a safe, effective and clinically acceptable VSV-based HIV vaccine, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2017-04-01 to 2020-03-31
  • Journée de la recherche de la Faculté de médecine, Subvention, Institutionnel - BDR, Fonds général de recherche du CRSNG, from 2010-11-24 to 2020-03-31
  • Possible outcomes of Leishmania co-infection on HIV-1 immunopathogenesis, latency and reactivation., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-07-01 to 2019-06-30
Data provided by the Université Laval research projects registery